The FDA has approved lenacapavir, which is branded as Yeztugo®, a groundbreaking injectable drug providing HIV prevention with just two shots a year. This treatment, developed by Gilead Sciences, is the first of its kind to offer six months of protection against HIV, marking a significant advancement in pre-exposure prophylaxis (PrEP) methods. Researchers suggest that the cost of this effective medication could be as low as $25 per patient per year. With an efficacy rate of up to 99.9%, lenacapavir signals a transformative moment in HIV prevention, raising hopes for a potential end to the HIV epidemic.